Table 3. Univariate Cox proportional hazards analysis of clinicopathological characteristics and clinical outcomes in 322 HBV-related HCC patients after PSM.
| Variables | Patients (n=322) | Overall survival | Disease-free survival | |||||
|---|---|---|---|---|---|---|---|---|
| MST (months) | HR* (95% CI) | P* | MRT (months) | HR* (95% CI) | P* | |||
| TP53 249Ser mutation | ||||||||
| Non-mutation | 161 | 57 | 1 | 11 | 1 | |||
| Mutation | 161 | 42 | 1.27 (0.92–1.75) | 0.146 | 6 | 1.16 (0.83–1.63) | 0.351 | |
| Age (years) | ||||||||
| ≤46 | 162 | 57 | 1 | 7 | 1 | |||
| >46 | 160 | 48 | 0.88 (0.64–1.21) | 0.438 | 12 | 0.78 (0.56–1.09) | 0.151 | |
| Gender | ||||||||
| Male | 284 | 48 | 1 | 7 | 1 | |||
| Female | 38 | 51 | 0.66 (0.366–1.19) | 0.166 | 12 | 0.89 (0.52–1.53) | 0.673 | |
| Race | ||||||||
| Han | 195 | 48 | 1 | 8 | 1 | |||
| Minority | 127 | 51 | 1.03 (0.74–1.43) | 0.868 | 8 | 1.22 (0.87–1.72) | 0.243 | |
| BMI | ||||||||
| ≤25 | 265 | 45 | 1 | 9 | 1 | |||
| >25 | 57 | 51 | 0.93 (0.61–1.40) | 0.719 | 7 | 1.29 (0.88–1.89) | 0.195 | |
| Smoking status | ||||||||
| None | 210 | 61 | 1 | 9 | 1 | |||
| Ever | 112 | 40 | 1.20 (0.86–1.67) | 0.275 | 6 | 1.04 (0.73–1.47) | 0.839 | |
| Drinking status | ||||||||
| None | 195 | 57 | 1 | 8 | 1 | |||
| Ever | 127 | 41 | 1.26 (0.91–1.74) | 0.158 | 7 | 1.03 (0.73–1.45) | 0.873 | |
| TP53 expressiona | ||||||||
| Negative | 94 | 45 | 1 | 12 | 1 | |||
| Positive | 179 | 42 | 1.08 (0.75–1.58) | 0.673 | 6 | 1.04 (0.71–1.52) | 0.838 | |
| TACE status | ||||||||
| Before hepatectomy | ||||||||
| No | 257 | 57 | 1 | 9 | 1 | |||
| Yes | 65 | 44 | 1.07 (0.73–1.58) | 0.720 | 6 | 1.37 (0.88–1.95) | 0.190 | |
| After hepatectomy | ||||||||
| No | 144 | 88 | 1 | 14 | 1 | |||
| Yes | 178 | 42 | 1.16 (0.84–1.62) | 0.368 | 6 | 1.64 (1.13–2.40) | 0.010 | |
| BCLC stage | ||||||||
| A | 200 | 84 | 1 | <0.001 | 12 | 1 | 0.030 | |
| B | 50 | 71 | 1.63 (1.05–2.53) | 0.031 | 6 | 1.19 (0.75–1.90) | 0.456 | |
| C | 72 | 17 | 3.31 (2.29–4.78) | <0.001 | 2 | 1.70 (1.15–2.53) | 0.008 | |
| Child–Pugh class | ||||||||
| A | 261 | 57 | 1 | 7 | 1 | |||
| B | 61 | 34 | 1.57 (1.02–2.43) | 0.040 | 6 | 1.22 (0.75–2.00) | 0.428 | |
| Cirrhosis | ||||||||
| No | 37 | 88 | 1 | 38 | 1. | |||
| Yes | 285 | 45 | 1.55 (0.89–2.68) | 0.122 | 7 | 1.79 (0.94–3.41) | 0.077 | |
| Antiviral therapy | ||||||||
| No | 214 | 58 | 1 | 6 | 1 | |||
| Yes | 108 | NA | 0.54 (0.36–0.81) | 0.003 | 13 | 0.62 (0.44–0.90) | 0.010 | |
| AFP (ng/mL)b | ||||||||
| ≤400 | 165 | 61 | 1 | 12 | 1 | |||
| >400 | 132 | 41 | 1.22 (0.87–1.72) | 0.246 | 7 | 1.08 (0.76–1.54) | 0.661 | |
| Radical resection | ||||||||
| Yes | 204 | 71 | 1 | 11 | 1 | |||
| No | 118 | 36 | 1.59 (1.15–2.19) | 0.005 | 5 | 1.60 (1.14–2.24) | 0.007 | |
| Pathological gradec | ||||||||
| Good | 19 | NA | 1 | 0.496 | 6 | 1 | 0.164 | |
| Moderate | 251 | 48 | 1.61 (0.71–3.66) | 0.255 | 7 | 1.54 (0.67–3.56) | 0.308 | |
| Poor | 11 | NA | 1.33 (0.38–4.73) | 0.656 | 3 | 3.18 (0.95–10.68) | 0.061 | |
| Oncological features | ||||||||
| Tumor size | ||||||||
| ≤5 cm | 106 | 123 | 1 | 17 | 1 | |||
| >5 cm | 216 | 41 | 1.9 (1.31–2.82) | 0.001 | 5 | 1.81 (1.25–2.62) | 0.002 | |
| No. of tumors | ||||||||
| Single (n=1) | 240 | 51 | 1 | 11 | 1 | |||
| Multiple (n>1) | 82 | 39 | 1.38 (0.97–1.96) | 0.072 | 6 | 1.15 (0.79–1.68) | 0.456 | |
| Capsule | ||||||||
| Complete | 124 | 95 | 1 | 0.002 | 14 | 1 | 0.014 | |
| Incomplete | 147 | 36 | 1.51 (0.93–2.46) | 0.099 | 5 | 1.21 (0.71–2.06) | 0.489 | |
| Absence | 51 | 51 | 1.93 (1.33–2.78) | <0.001 | 8 | 1.72 (1.19–2.48) | 0.004 | |
| Regional invasion | ||||||||
| Absence | 275 | 57 | 1 | 11 | 1 | |||
| Presence | 47 | 40 | 1.32 (0.84–2.08) | 0.235 | 2 | 1.80 (1.17–2.77) | 0.008 | |
| Intrahepatic metastasis | ||||||||
| Absence | 179 | 75 | 1 | 12 | 1 | |||
| Presence | 143 | 36 | 1.60 (1.16–2.20) | 0.004 | 4 | 1.54 (1.10–2.15) | 0.012 | |
| Vascular invasion | ||||||||
| Absence | 270 | 73 | Ref. | 9 | 1 | |||
| Presence | 52 | 12 | 3.40 (2.32–5.00 | <0.001 | 2 | 1.57 (1.03–2.40) | 0.036 | |
| PVTT | ||||||||
| No | 276 | 71 | Ref. | <0.001 | 11 | 1 | 0.014 | |
| vp1 | 6 | 7 | 4.67 (1.70–12.84) | 0.003 | 1 | 2.29 (0.73–7.24) | 0.158 | |
| vp2 | 11 | 17 | 4.16 (1.53–6.52) | <0.002 | 2 | 2.24 (0.82–6.13) | 0.117 | |
| vp3 | 24 | 12 | 3.00 (1.80–5.00) | <0.001 | 3 | 1.43 (0.80–2.55) | 0.226 | |
| vp4 | 5 | 8 | 6.52 (2.37–17.94) | <0.001 | 1 | 4.49 (1.61–12.55) | 0.004 | |
P<0.05 is statistically significant. a, TP53 expression information was unavailable for 49 patients. b, AFP information was unavailable for 25 patients. c, pathological grade information was unavailable for 41 patients. *, HR and P value for univariate survival analysis of Cox proportional hazard regression model. AFP, alpha-fetoprotein; TACE, transarterial chemoembolization; BMI, body mass index; PVTT, portal vein tumor thrombus; MST, median survival time; MRT, median recurrence time; HR, hazard ratio; 95% CI, 95% confidence interval.